Canada's Zymeworks raises 2026 revenue and EBITDA guidance
ZYME•Zymeworks raised its 2026 revenue guidance to $337 million-$351 million from $278 million-$292 million and adjusted EBITDA guidance to $176 million-$190 million from $114 million-$128 million. Third-quarter revenue surged year over year, driven by a $250 million milestone payment from Jazz.
1. Raised 2026 guidance
Zymeworks raised its 2026 revenue guidance to $337 million-$351 million, from $278 million-$292 million, and its adjusted EBITDA guidance to $176 million-$190 million, from $114 million-$128 million. The company expects $13 million-$15 million in annualized cost savings from its Theravance Biopharma acquisition.
2. Quarterly results
Third-quarter revenue surged year over year, driven by a $250 million milestone payment from Jazz after U.S. approval of Ziihera for first-line HER2-positive GEA. Zymeworks posted net income, reversing a loss in the year-earlier period. YUPELRI collaboration revenue rose 4% year over year, with hospital-channel doses growing at a double-digit rate.
